Illumina, Inc. (ILMN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $205.00. The rating moved from Neutral to Overbought on August 19, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$205.00
• Last changeMoved from Neutral to Overbought on August 19, 2026
• SectorHealthcare
• IndustryDiagnostics & Research

See all overbought Healthcare stocks →

AI analysis

Illumina, Inc. (ILMN) sits as a dominant NGS platform provider with a resilient consumables‑driven revenue model and clear exposure to expanding oncology and gene‑therapy diagnostic workflows. Near‑term market activity is neutral, supporting stable order flow while sector tailwinds around diagnostics and biologics provide meaningful growth optionality. Key risks include cyclical capital spending, competitive pressure, and regulatory/reimbursement uncertainty that can create headline volatility. Over the next month the company’s strong installed base, product roadmap, and recurring revenue mix support upside potential if execution remains consistent.

Key factors

• Market leadership in next‑generation sequencing (NGS) with a large installed base and recurring consumables revenue provides a durable cash flow backbone.
• Growing demand for oncology diagnostics, screening and advanced genomic applications aligns with sector tailwinds that can expand lab and clinical volumes.
• Exposure to biologics/CDMO and gene‑therapy supply chain expansion supports demand for analytical testing and sequencing services.
• Product roadmap and software/AI workflow improvements can drive higher instrument attach rates, better consumables mix, and margin expansion over time.
• Neutral near‑term macro backdrop with steady order flow; limited headline risk in the immediate window supports stable execution versus volatile growth peers.

Risks

• Cyclical and lumpy capital spending by large customers can depress instrument sales and create volatile quarter‑to‑quarter results.
• Intense competition from large life‑science players (Thermo Fisher, BGI and others) on pricing, platform breadth and service offerings.
• Regulatory, reimbursement and payer dynamics could limit clinical adoption or slow reimbursement for certain assays and diagnostic workflows.
• Legal or antitrust overhangs and legacy contract disputes could re‑emerge and weigh on sentiment or cash flow.
• Supply‑chain constraints, FX exposure, or execution missteps on new product launches that delay revenue recognition.

Latest MarketMoodz coverage

• Trump's China trip includes Apple, Tesla chiefs among 17 executives2026-05-13

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.